Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Xeris Biopharma Holdings, Inc. (XERS)
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Year-to-Date Net Product Revenue: $139.6 million, a 26% increase compared to the prior year. Year-to-Date Total Revenue: $143 million, a 20% increase compared to the prior year. Recorlev Net Revenue: $17.7 million for the quarter, more than doubling compared to the prior year. Gvoke Net Revenue: $22.9 million for the quarter, a 29% increase compared to the prior year. Keveyis Net Revenue: $12.2 million for the quarter. Cash Position: Over $69 million at the end of the quarter. Cost of Goods Sold: 25.7% of total product revenue for the quarter. Research and Development Expenses: $5.9 million for the third quarter. Selling, General and Administrative Expenses: $45 million for the quarter, a 21% increase compared to the prior year. Revenue Guidance: Raised to $198 to $202 million for the year. Cash Guidance: Tightened to $68 to $72 million by year-end 2024. Warning! GuruFocus has detected 5 Warning Signs with XERS. Release Date: November 08, 2024 For the comple
Show less
Read more
Impact Snapshot
Event Time:
XERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XERS alerts
High impacting Xeris Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
XERS
News
- Analysts Expect Breakeven For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Before Long [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its price target raised by analysts at HC Wainwright from $6.00 to $6.60. They now have a "buy" rating on the stock.MarketBeat
- Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) was downgraded by analysts at Piper Sandler from an "overweight" rating to a "neutral" rating. They now have a $3.00 price target on the stock.MarketBeat
- Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma Reports Third Quarter 2024 Financial ResultsBusiness Wire
XERS
Earnings
- 11/8/24 - Miss
XERS
Sec Filings
- 11/8/24 - Form 10-Q
- 11/8/24 - Form 8-K
- XERS's page on the SEC website